Startseite Medizin Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on pulmonary function in hypertensive patients
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on pulmonary function in hypertensive patients

  • Azza S. Jabbar , Nadheera F. Neamah und Ahmed H. Al-Darraji ORCID logo EMAIL logo
Veröffentlicht/Copyright: 15. März 2021

Abstract

Objectives

Hypertension is a very common cardiovascular disease. Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs) are widely used to treat hypertension. Many patients with hypertension are vulnerable to the antihypertensive adverse effects, which potentially reduces the adherence rate. Therefore, we conducted this study in order to evaluate the safety profile of both classes (ACEi and ARBs) on respiratory functions.

Methods

Two main groups of subjects were studied: first group is healthy control subjects and the second group is hypertensive patients, which was subdivided into subgroups in order to investigate the effect of all tested medications (captopril, enalapril, lisinopril, losartan, and valsartan). Respiratory efficiency was evaluated by measuring pulmonary function tests: FEV1, FVC, and FEV1%. Measurements were done using micromedical spirometer.

Results

We found that ARBs do not impair normal respiratory functions as measured by FEV1, FEV1%, and FVC in hypertensive patients. While ACEi treatments significantly reduced FEV1, FEV1%, and FVC compared to the other groups.

Conclusions

ARBs are not associated with any harmful effects on respiratory functions in hypertensive patients, unlike ACEi. As such, they could represent a first-choice treatment for hypertensive patients who are at high risk to the respiratory adverse effects.


Corresponding author: Ahmed H. Al-Darrahi, Department of Pharmacology and Toxicology, University of Barsah, Basrah, Iraq, E-mail:

Acknowledgments

None.

  1. Research funding: None declared.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Informed consent: Informed consent was obtained from all individuals included in this study.

  5. Ethical approval: Scientific and ethical committees in the College of pharmacy, Basrah University approved this study.

References

1. Birhan, MM, Abebe, Y. Pulmonary function tests in hypertensive patients attending Zewditu Memorial Hospital, Addis Ababa, Ethiopia. Int J Hypertens 2018;2018:5492680.10.1155/2018/5492680Suche in Google Scholar

2. Schnabel, E, Karrasch, S, Schulz, H, Glaser, S, Meisinger, C, Heier, M, et al.. High blood pressure, antihypertensive medication and lung function in a general adult population. Respir Res 2011;12:50.10.1186/1465-9921-12-50Suche in Google Scholar PubMed PubMed Central

3. Schnabel, E, Nowak, D, Brasche, S, Wichmann, HE, Heinrich, J. Association between lung function, hypertension and blood pressure medication. Respir Med 2011;105:727–33.10.1016/j.rmed.2010.12.023Suche in Google Scholar

4. Tom, B, Dendorfer, A, de Vries, R, Saxena, PR, Jan Danser, AH. Bradykinin potentiation by ACE inhibitors: a matter of metabolism. Br J Pharmacol 2002;137:276–84.10.1038/sj.bjp.0704862Suche in Google Scholar

5. Packard, KA, Wurdeman, RL, Arouni, AJ. ACE inhibitor-induced bronchial reactivity in patients with respiratory dysfunction. Ann Pharmacother 2002;36:1058–67.10.1345/aph.1A332Suche in Google Scholar

6. Abdi, R, Dong, VM, Lee, CJ, Ntoso, KA. Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema. Pharmacotherapy 2002;22:1173–5.10.1592/phco.22.13.1173.33517Suche in Google Scholar

7. Ong, HT, Ong, LM, Ho, JJ. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) in patients at high risk of cardiovascular events: a meta-analysis of 10 randomised placebo-controlled trials. ISRN Cardiol 2013;2013:478597.10.1155/2013/478597Suche in Google Scholar

8. Elliott, WJ, Calhoun, DA, DeLucca, PT, Gazdick, LP, Kerns, DE, Zeldin, RK. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clin Therapeut 2001;23:1166–79.10.1016/S0149-2918(01)80099-0Suche in Google Scholar

9. Hedner, T, Oparil, S, Rasmussen, K, Rapelli, A, Gatlin, M, Kobi, P, et al.. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens 1999;12:414–7.10.1016/S0895-7061(99)00082-5Suche in Google Scholar

10. Schnabel, E, Karrasch, S, Schulz, H, Gläser, S, Meisinger, C, Heier, M, et al.. High blood pressure, antihypertensive medication and lung function in a general adult population. Respir Res 2011;12:50.10.1186/1465-9921-12-50Suche in Google Scholar

11. Kanazawa, H, Hirata, K, Yoshikawa, J. Imbalance between vascular endothelial growth factor and endostatin in emphysema. Eur Respir J 2003;22:609–12.10.1183/09031936.03.00030403Suche in Google Scholar PubMed

12. Kanazawa, H, Hirata, K, Yoshikawa, J. Effects of captopril administration on pulmonary haemodynamics and tissue oxygenation during exercise in ACE gene subtypes in patients with COPD: a preliminary study. Thorax 2003;58:629–31.10.1136/thorax.58.7.629Suche in Google Scholar PubMed PubMed Central

13. Williams, B. Drug discovery in renin-angiotensin system intervention: past and future. Ther Adv Cardiovasc Dis 2016;10:118–25.10.1177/1753944716642680Suche in Google Scholar PubMed PubMed Central

14. Kanazawa, H, Hirata, K, Yoshikawa, J. Influence of oxygen administration on pulmonary haemodynamics and tissue oxygenation during exercise in COPD patients with different ACE genotypes. Clin Physiol Funct Imag 2003;23:332–6.10.1046/j.1475-0961.2003.00515.xSuche in Google Scholar PubMed

15. Pinargote, P, Guillen, D, Guarderas, JC. ACE inhibitors: upper respiratory symptoms. BMJ Case Rep 2014;2014.10.1136/bcr-2014-205462Suche in Google Scholar PubMed PubMed Central

16. Bhatt, SP, Soler, X, Wang, X, Murray, S, Anzueto, AR, Beaty, TH, et al.. Association between functional small airway disease and FEV1 decline in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2016;194:178–84.10.1164/rccm.201511-2219OCSuche in Google Scholar PubMed PubMed Central

17. Bhatt, SP, Terry, NL, Nath, H, Zach, JA, Tschirren, J, Bolding, MS, et al.. Association between expiratory central airway collapse and respiratory outcomes among smokers. J Am Med Assoc 2016;315:498–505.10.1001/jama.2015.19431Suche in Google Scholar PubMed PubMed Central


Supplementary Material

The online version of this article offers supplementary material (https://doi.org/10.1515/jbcpp-2020-0243).


Received: 2020-09-10
Accepted: 2020-12-21
Published Online: 2021-03-15

© 2021 Walter de Gruyter GmbH, Berlin/Boston

Heruntergeladen am 26.1.2026 von https://www.degruyterbrill.com/document/doi/10.1515/jbcpp-2020-0243/html
Button zum nach oben scrollen